Nurix Advances Targeted Protein Degradation Pipeline with Clinical and Partnership Milestones Nurix Therapeutics (Nasdaq: NRIX) is gaining traction as its stock rose 20% in premarket trading after the company reported second quarter 2025 results yesterda

#NurixTherapeutics #NRIX surged 20% as Nurix Therapeutics ramps up progress in targeted protein degradation. With new CLL data, pivotal trials ahead, and expanded deals with #Gilead #GILD and #Sanofi #SNY, this biotech is gaining serious traction.
Full Story: prismmarketview.com/nurix-advanc...

Nurix Reports Durable, Deepening Responses With Bexobrutideg in Hard-to-Treat Blood Cancers Nurix Therapeutics (NASDAQ: NRIX) presented new clinical data at EHA 2025 showing sustained responses with its investigational BTK degrader bexobrutideg (NX-594

#NRIX Delivers Promising Results in Blood Cancer Fight
Nurix has reported durable and deepening responses with its investigational therapy Bexobrutinib (NX-2127) in patients with hard-to-treat blood cancers.
#NurixTherapeutics
prismmarketview.com/nurix-report...

Nurix Therapeutics has Received FDA’s Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia - OncoDaily Nurix Therapeutics has Received FDA’s Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia / Arthur T. Sands, cancer, EMA PRIME Designation,

Nurix Therapeutics has Received FDA’s Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia

oncodaily.com/drugs/nurix-...

#Cancer #EMA #PRIMEDesignation #FDA #Medicine #FastTrackDesignation #NurixTherapeutics #OncoDaily #Oncology #Health